Unravelling the best combination of therapies to treat anaplastic thyroid cancer

Abate, Ejigayehu G.; Smallridge, Robert C.

doi:10.1080/17446651.2016.1179109

Cited by 5 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy can provide short‐duration disease control in a small proportion of patients. Small clinical trials with agents targeting molecular aberrations are under investigation . To date, none of these targeted agents are Food and Drug Administration (FDA)‐approved.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CD70 and PD‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Although mutations in various oncogenes (e.g. BRAF , RAS PIK3CA ) have been identified, tailored targeted therapies are currently lacking for ATC …”

Section: Introductionmentioning

confidence: 99%

CD70 and PD‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, the 2.5-year survival rate is only 50% using such treatment regimens in this subset of patients [ 5 , 6 ]. There is no effective treatment for metastatic ATC (stage IVC) that consists of approximately 40-60% of all ATC patients at the time of diagnosis [ 7 – 9 ]. Novel therapies with different mechanisms of activity are needed to improve the outcomes of patients with this dismal disease.…”

Section: Introductionmentioning

confidence: 99%

Effects of roniciclib in preclinical models of anaplastic thyroid cancer

Lin¹,

Lin²,

Chou³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Many human cancers have altered cyclin-dependent kinase activity. Inhibition of cyclin-dependent kinases may arrest cell cycle progression and represents an important strategy in the treatment of malignancies. We evaluated the therapeutic effects of roniciclib, a cyclin-dependent kinase inhibitor, as a treatment for anaplastic thyroid cancer. Roniciclib inhibited anaplastic thyroid cancer cell proliferation in a dose-dependent manner. Roniciclib activated caspase-3 activity and induced apoptosis. Cell cycle progression was arrested in G2/M phase. In vivo, the growth of anaplastic thyroid cancer xenograft tumors was retarded by roniciclib treatment without evidence of toxicity. These data provide a rationale for further clinical evaluation using roniciclib in the treatment of patients with anaplastic thyroid cancer.

show abstract

“…Distant metastases are present at diagnosis in about one third of patients. Common sites of metastases are lung, local lymph nodes, intrathoracic lymph nodes, liver, and brain 13 . Surgery is the cornerstone of management in ATC and is associated with longer overall survival (OS) and progression-free survival (PFS) in stages IVA and IVB.…”

Section: Introductionmentioning

confidence: 99%

“…By definition ATC is a stage IV disease which is subdivided into A, B, C according to local and distant metastases 13 . Distant metastases are present at diagnosis in about one third of patients.…”

Section: Introductionmentioning

confidence: 99%

Treatment Outcome and Prognostic Factors of Anaplastic Thyroid Carcinoma: A Single Institution Experience in Egypt

Ibrahim

Askoura

2018

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

Introduction: Anaplastic thyroid carcinoma (ATC) is a rare lethal malignancy. It is one of the most aggressive human malignancies with limited progress in finding effective therapies. Aim: We aimed to study the treatment outcome and prognostic factors of ATC patients treated at our institution. Methods: We retrospectively analyzed charts of 30 ATC patients, treated at the Clinical Oncology Department, AinShams University from 2006 to 2017. The clinical characteristics and factors affecting survival were studied. Kaplan-Meier survival curve was used to analyze the overall survival (OS) of the patients. Results: The median age of patients was 60 years and males represented 63% of them. Almost half of patients (47%) had stage IVA disease. Equal number of patients received combined modality treatment versus single modality treatment (37% each). The median OS was 3 months (95% Confidence interval: 1.429-4.571). Variables associated with significantly better OS in univariate analysis included male sex (p=0.04), stage IVA disease (p=0.012), surgical treatment (p=0.034), radiotherapy (p=0.003), and combined modality treatment (p=0.005). However, only female sex was identified as significant poor prognostic variable of OS (p=0.043) by multivariate analysis. Conclusion: Our results of treatment outcome and prognosis of ATC agree with most of the literature. Multimodality treatment is currently the standard of care. While still there is no successful treatment of this rapidly fatal disease, exploration of novel therapies and approaches are warranted to help improve the outcome.

show abstract

Unravelling the best combination of therapies to treat anaplastic thyroid cancer

Cited by 5 publications

References 19 publications

CD70 and PD‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy

CD70 and PD‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy

Effects of roniciclib in preclinical models of anaplastic thyroid cancer

Treatment Outcome and Prognostic Factors of Anaplastic Thyroid Carcinoma: A Single Institution Experience in Egypt

Contact Info

Product

Resources

About